Basecamp Research secures 140 million dollars in Series C funding
Biotechnology company Basecamp Research raised 140 million dollars in Series C funding led by venture firm S32 to advance its biological foundation models and cell therapies
Basecamp Research has secured $140 million in Series C funding to advance AI-designed therapeutics, announced on September 23, 2026. The funds, led by S32 and including NVIDIA, Menlo Ventures, Anthology Fund, and several other investors, will support the development of EDEN-designed medicines and expand pharmaceutical partnerships.
Basecamp's ambition is to create cures for diseases currently deemed incurable by designing medicines that reprogram the body to repair itself. The company's EDEN models, trained on a proprietary Trillion Gene Atlas, aim to generate therapeutic candidates directly from disease information. With strong preclinical results across multiple modalities and disease areas, Basecamp Research is poised to transform the future of medicine through its unique AI-driven approach.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
